Touchlight Highlights Potential Efficiency Gains in Lentiviral Vector Production

According to a recent LinkedIn post from Touchlight, new experimental data suggest its dbDNA™ platform, when used with FuGENE 4K transfection reagent, may substantially increase lentiviral vector production relative to traditional plasmid DNA. The shared results describe a comparative study using third‑generation LVV systems in HEK293T cells.

The post highlights up to threefold higher infectious titres in adherent cultures and a twofold increase in infectious titres while using 50% less total DNA and transfection reagent. It also reports 2.4× higher titres in a scalable suspension LVV production process, with the company directing readers to an external application note for detailed data.

For investors, the data, if validated and adopted broadly, could position dbDNA™ as a more efficient and potentially lower cost backbone for lentiviral manufacturing workflows. This may enhance Touchlight’s value proposition in the gene and cell therapy supply chain, supporting pricing power, higher-margin service or licensing opportunities, and deeper partnerships with vector manufacturers and biopharma developers.

Improved LVV yields and reduced reagent use are commercially relevant in an industry where vector supply and cost of goods remain key bottlenecks. If the performance gains described translate at commercial scale, Touchlight could benefit from increased demand for its technology and strengthened competitive differentiation versus conventional plasmid-based approaches.